A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors

EMD Serono Research & Development Institute, Inc.19 sites in 6 countries52 target enrollmentNovember 8, 2024

ConditionsAdvanced Solid Tumor

InterventionsM3554

Overview

Phase: Phase 1
Intervention: M3554
Conditions: Advanced Solid Tumor
Sponsor: EMD Serono Research & Development Institute, Inc.
Enrollment: 52
Locations: 19
Primary Endpoint: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)
Status: Recruiting
Last Updated: 17 days ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype.

Study details include:

Study Duration per participant: Approximately 4 months

Registry

clinicaltrials.gov

Start Date

November 8, 2024

End Date

April 16, 2027

Last Updated

17 days ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

EMD Serono Research & Development Institute, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Escalation A: participants with documented histopathological diagnosis of locally advanced or metastatic STS with unresectable disease that has progressed after at least one prior line of anthracycline-containing systemic therapy for the locally advanced/metastatic setting.
•Participants with resectable locally advanced or metastatic disease, who had surgery before study entry will be allowed in the trial if there is residual disease after surgery and if the surgery was performed at least 4 weeks before first dose of study intervention.
•Escalation B: participants with documented histopathological diagnosis of glioblastoma, IDH-wildtype, who have progressed after ONLY one prior line of therapy (including radiotherapy +/- temozolomide, depending on the O\^6-methylguanine-DNA methyltransferase \[MGMT\] status) and relapsing at least 3 months after the end of the radiotherapy treatment.
•Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1
•Participants with adequate hematologic, hepatic and renal function as defined in protocol
•Other protocol defined inclusion criteria could apply

Exclusion Criteria

•Participant has a history of malignancy other than STS or glioblastoma (depending on the escalation/expansion cohort) within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, is considered cured with minimal risk of recurrence within 3 years).
•STS only: Participants with history of brain metastasis, leptomeningeal metastasis, or participants with spinal cord compression
•Other protocol defined exclusion criteria could apply

Arms & Interventions

Dose Escalation: M3554 Monotherapy

Intervention: M3554

Outcomes

Primary Outcomes

Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)

Time Frame: up to 4 months

Secondary Outcomes

Change from Baseline in Corrected QT Interval (QTc) Interval(Pre-dose on Day 1 (baseline) up to 24 hours post-dose Day 1, Day 2, Day 5, Day 8 of Cycle 1 and Cycle 3 Day 1 (each Cycle is 21 days))
Pharmacokinetic (PK) Plasma Concentrations of M3554(Cycle 1 Day 1 to Cycle 3 Day 15 and every second cycle from Cycle 4 (each cycle is of 21 days), assessed up to approximately 4 months)
Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 as Assessed by Investigator(Time from randomization to planned assessment at 4 months)
Duration of Response (DoR) According to RECIST Version 1.1 or RANO 2.0 as Assessed by Investigator(Time from randomization to planned assessment at 4 months)
Progression-free Survival (PFS) According to RECIST Version 1.1 or RANO 2.0 as Assessed by Investigator(Time from randomization to planned assessment at 4 months)